AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11077646
Drug: Monthly combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly combination injectable contraceptive
Trial: 8828437
Drug: Maternal magnesium
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal magnesium sulfate administered intrapartum
Trial: 1380429
Drug: tropisetron 5mg
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tropisetron 5mg once daily for 5 days
Trial: 1380429
Drug: conventional antiemetic
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conventional antiemetic drugs
Trial: 19934029
Drug: LCZ696 (200-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 (200-1200 mg single-dose; 50-900 mg once daily for 14 days)
Trial: 7848353
Drug: Ben-u-ron 500
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ben-u-ron 500 mg suppositories
Trial: 7848353
Drug: Ben-u-ron 1000
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ben-u-ron 1000 mg suppositories
Trial: 25471688
Drug: Intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline (placebo)
Trial: 21296449
Drug: 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 docetaxel (arm C)
Trial: 21296449
Drug: 50 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 escalated to 70 mg/m2 docetaxel (arm D)
Trial: 31014270
Drug: Tolvaptan therapy
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan therapy
Trial: 17873626
Drug: OPTI-FREE RepleniSH
RxNorm normalized name: Opti-Free RepleniSH Multi-Purpose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPTI-FREE RepleniSH Multi-Purpose Disinfecting Solution (regimen 1)
Trial: 17873626
Drug: ReNu MultiPlus
RxNorm normalized name: ReNu MultiPlus No-Rub Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReNu MultiPlus Multi-Purpose Solution No Rub Formula (regimen 2)
Trial: 17873626
Drug: Complete MoisturePLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete MoisturePLUS Multi-Purpose Solution (regimen 3)
Trial: 11730396
Drug: Indinavir, zidovudine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir, zidovudine, and lamivudine therapy
Trial: 7740330
Drug: Intravenous vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vinorelbine
Trial: 2225410
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg t.i.d.
Trial: 2225410
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg and dipyridamole 75 mg t.i.d.
Trial: 103467
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg or 450 mg daily of oral papaverine
Trial: 28012023
Drug: Subcutaneous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous methotrexate (MTX) administered via auto-injector into the abdomen (MTXAIab)
Trial: 28012023
Drug: Subcutaneous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous methotrexate (MTX) administered via auto-injector into the thigh (MTXAIth)
Trial: 7945475
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (MTX)
Trial: 22943609
Drug: Six-month treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-month treatment program of pharmacotherapy, standardized patient and provider education, and physician and patient counseling
Trial: 17599629
Drug: epalrestat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epalrestat (50 mg/day p.o. ac, t.i.d.)
Trial: 21810288
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose oat β‐glucan (3·0 g β‐glucan; oats high ‐ OH)
Trial: 15117834
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine challenge (DSMR)
Trial: 892957
Drug: Pindolol 5
RxNorm normalized name: pindolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 5 mg, three times daily for 6 weeks
Trial: 16371411
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² every 3 weeks (3W arm)
Trial: 10906101
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C application during DCR surgery (0.2 mg/ml for 30 minutes)
Trial: 9289023
Drug: Parenteral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral group (group 3)
Trial: 8513961
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg RU486 (single dose)
Trial: 2426419
Drug: Vinblastine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine 0.3 mg/kg/cycle
Trial: 23272529
Drug: Adaptogens (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptogens (multiple dose administration, twice daily) plus standard prevention protocol (lifestyle counseling)
Trial: 10441602
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of immunotherapy
Trial: 10441602
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of immunotherapy
Trial: 10441602
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (continuation and discontinuation)
Trial: 7801862
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem (bolus dose followed by continuous infusion at 5, 10, and 15 mg/hour)
Trial: 7801862
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of diltiazem at 5 mg/hour
Trial: 7801862
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of diltiazem at 10 mg/hour
Trial: 27707436
Drug: PAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP therapy
Trial: 24479361
Drug: Saline 2
RxNorm normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 2 ml, intravenous injection, twice a day (Control)
Trial: 24479361
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg (2 ml), intravenous injection, twice a day
Trial: 8231902
Drug: 50 micrograms/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms/day transdermal oestradiol (E2) cyclically (n = 20)
Trial: 8231902
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day CEE continuously (n = 15)
Trial: 8231902
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day CEE and 2.5 mg/day of MPA continuously (n = 20)
Trial: 29105855
Drug: Dicloxacillin 1
RxNorm normalized name: dicloxacillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicloxacillin 1 g three times daily for 10 days
Trial: 24879757
Drug: Ractopamine hydrochloride
RxNorm normalized name: ractopamine hydrochloride
DrugBank: Ractopamine (DB11541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ractopamine hydrochloride (RH; 308 mg·head(‐1)·d(‐1) for 28 d)
Trial: 8509523
Drug: Moclobemide (MAO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (MAO inhibitor), fixed-dose schedule for 4 weeks
Trial: 3620290
Drug: Sulpiride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (1 mg, 10 mg, 50 mg)
Trial: 3620290
Drug: Sulpiride (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (chronic treatment)
Trial: 27717552
Drug: IKH‐01 (0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IKH‐01 (0.035 mg ethinyl estradiol and 1 mg norethisterone)
Trial: 19439099
Drug: Narrative Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Exposure Therapy for children (KIDNET)
Trial: 16890599
Drug: Peginterferon-alfa2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon-alfa2a (180 microg/wk) plus ribavirin (800 mg/day) for 72 weeks (group B)
Trial: 16890599
Drug: Peginterferon-alfa2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon-alfa2a (180 microg/wk) plus ribavirin (800 mg/day) for 48 weeks (group A)
Trial: 3234469
Drug: Maprotiline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (50 mg b.d. for 15 days)
Trial: 29948023
Drug: INTP5 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INTP5 (3 mg/0.3 ml)
Trial: 29948023
Drug: INTP5 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INTP5 (6 mg/0.6 ml)
Trial: 29948023
Drug: Neulasta (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neulasta (3 mg/0.3 ml)
Trial: 29948023
Drug: Neulasta (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neulasta (6 mg/0.6 ml)
Trial: 23605244
Drug: TLLS+ (transmeatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLLS+ (transmeatal low-power laser stimulation at 5 mW, 650 nM wavelength for 20 min daily and oral betahistine 24 mg twice per day for 10 weeks)
Trial: 23605244
Drug: TLLS- (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLLS- (placebo device and oral betahistine 24 mg twice per day for 10 weeks)
Trial: 12901286
Drug: 3MU alpha
RxNorm normalized name: Alpha Arbutin
DrugBank: alpha-Arbutin (DB14109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3MU alpha N1‐IFN daily for 10 days every 3 months
Trial: 12901286
Drug: Reduced dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced dosage of alpha N1‐IFN or stopped interferon therapy or received 30MU dose at 6‐month intervals
Trial: 10028075
Drug: Azithromycin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (750 mg loading dose followed by 250 mg/d)
Trial: 10028075
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg/d)
Trial: 29419337
Drug: Hatha Yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hatha Yoga intervention (twice‐weekly, 60‐minute sessions for 8 weeks)
Trial: 23469597
Drug: Dujieqing Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dujieqing Oral Liquid (DJQ) combined with conventional chemotherapy
Trial: 18030066
Drug: Clopidogrel 600-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600-mg
Trial: 12576937
Drug: Strict normalization
RxNorm normalized name: Euphrasia stricta extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict normalization of blood glucose (80‐110 mg/dL) with insulin infusion
Trial: 12576937
Drug: Conventional approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional approach (blood glucose levels at 180‐200 mg/dL)
Trial: 10697394
Drug: Insulin binding
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin binding to erythrocyte receptors in patients with essential hypertension
Trial: 10697394
Drug: Insulin concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin concentration in patients with essential hypertension
Trial: 10697394
Drug: Insulin degradation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin degradation by erythrocytes
Trial: 10697394
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between body weight and insulin concentration
Trial: 11870488
Drug: iodixanol 270
RxNorm normalized name: IODIXANOL 270mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodixanol 270 mgI/ml
Trial: 8793433
Drug: ioxaglate 320
RxNorm normalized name: ioxaglate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ioxaglate 320 mgI/ml
Trial: 1911585
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg orally 30 h before termination of pregnancy
Trial: 29282145
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care without supplemental parenteral nutrition
Trial: 18838420
Drug: New Zealand
RxNorm normalized name: NEW ZEALAND GREEN MUSSEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Zealand candidate vaccine (epidemic strain NZ98/254, B:4:P1.7b,4)
Trial: 12516995
Drug: Meningococcal C
RxNorm normalized name: meningococcal conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal C conjugate vaccine
Trial: 10509376
Drug: Diazepam (DZP)
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam (DZP) 5.0 mg p.o.
Trial: 8604671
Drug: Oral riboflavin
RxNorm normalized name: riboflavin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral riboflavin (20 mg)
Trial: 28207540
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg mifepristone
Trial: 24779241
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg mifepristone
Trial: 15883741
Drug: Filgrastim 300
RxNorm normalized name: FILGRASTIM 300MCG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim 300 microg once daily
Trial: 25061714
Drug: SOC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC therapy (Peg-interferon alfa-2b plus ribavirin)
Trial: 16968576
Drug: Once-daily ofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily ofloxacin otic solution (0.3%)
Trial: 16968576
Drug: Neomycin sulfate/polymyxin
RxNorm normalized name: neomycin sulfate/polymyxin B sulfate OPHTHALMIC DROPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension (four times daily)
Trial: 11282262
Drug: Sitafloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitafloxacin (400 mg once daily)
Trial: 11282262
Drug: Imipenem/cilastatin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (500 mg three times daily)
Trial: 8505664
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium diet (total calcium intake of 2200 mg/d)
Trial: 8505664
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium diet (240 mg Ca/d)
Trial: 20921118
Drug: Adolescent-focused individual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescent-focused individual therapy (AFT)
Trial: 25440306
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (FBT and AFT)
Trial: 22796132
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg esomeprazole twice daily + aspirin placebo once daily (arm A; n = 30)
Trial: 22796132
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg esomeprazole twice daily + 325 mg aspirin once daily (arm C; n = 45)
Trial: 18559649
Drug: Artemisone 10
RxNorm normalized name: Artemisone
DrugBank: Artemisone (DB16097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisone 10 mg
Trial: 18559649
Drug: Artemisone 20
RxNorm normalized name: Artemisone
DrugBank: Artemisone (DB16097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisone 20 mg
Trial: 18559649
Drug: Artemisone 30
RxNorm normalized name: Artemisone
DrugBank: Artemisone (DB16097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisone 30 mg
Trial: 18559649
Drug: Artemisone 40
RxNorm normalized name: Artemisone
DrugBank: Artemisone (DB16097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisone 40 mg (multiple doses for 3 days)
Trial: 18559649
Drug: Artemisone 80
RxNorm normalized name: Artemisone
DrugBank: Artemisone (DB16097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisone 80 mg (multiple doses for 3 days)
Trial: 15679068
Drug: Intravenous pamidronate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate, 3 mg/kg over 3 days every 4 months
Trial: 15679068
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate 1 mg/kg, from a minimum of 10 mg to a maximum of 20 mg daily
Trial: 12826145
Drug: Gengraf (generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gengraf (generic formulation of cyclosporine)
Trial: 7573711
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 6 mg of DEC/kg of body weight at an interval of six months (group 2)
Trial: 7573711
Drug: Community level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community level after group 1 treatment
Trial: 29130624
Drug: Reduced bleomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced bleomycin dose (10,000 IU/m2)
Trial: 29130624
Drug: Standard bleomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bleomycin dose (15,000 IU/m2)
Trial: 10077706
Drug: Free supplementary
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free supplementary insurance for complementary medicine
Trial: 7574745
Drug: Continuous arterial
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous arterial infusion of CDDP (10 mg/body) and 5-FU (250 mg/body) for 5 days, with 4 courses administered
Trial: 7574745
Drug: Continuous arterial
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous arterial infusion of CDDP and 5-FU for 24 hours
Trial: 2076713
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg daily)
Trial: 31914241
Drug: Luspatercept (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luspatercept (1.0 up to 1.75 mg/kg, subcutaneously every 3 weeks)
Trial: 19028953
Drug: Self-taken rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-taken rectal swabs for GC
Trial: 19028953
Drug: Self-taken rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-taken rectal swabs for CT
Trial: 19028953
Drug: Nurse-taken rectal
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-taken rectal swabs for CT
Trial: 12816777
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dried peas and potatoes (meal 2)
Trial: 10423609
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg quinapril once daily
Trial: 10423609
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg captopril twice daily
Trial: 1347260
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg d-1)
Trial: 1347260
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg day-1)
Trial: 1347260
Drug: Propranolol (80-480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80-480 mg)
Trial: 30426896
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous and intraperitoneal chemotherapy
Trial: 17617517
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy
Trial: 23726933
Drug: Pragmatic intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pragmatic intervention (n=49) including pharmaceutical management, multimodal physiotherapy, and psychology for post-traumatic stress.
Trial: 11746330
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (specific treatment not mentioned)
Trial: 11746330
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (specific treatment not mentioned)
Trial: 30130421
Drug: No-CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-CPAP treatment
Trial: 20236631
Drug: hMG+CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG+CC
Trial: 7493311
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group D)
Trial: 2058612
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 1.0 micrograms/kg/min for 72 hours
Trial: 2058612
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 2.5 micrograms/kg/min for 72 hours